Thursday, June 13, 2019
Gallup has this new story reporting on the results of its recent intriguing poll about marijuana reform under the headline "In U.S., Medical Aid Top Reason Why Legal Marijuana Favored." Here are excerpts:
As public support for legalizing marijuana has surged, a new Gallup poll finds 86% of U.S. supporters of legal marijuana saying its medicinal benefits are a very important reason they support legalization. Majorities also say freeing up police resources to focus on other crimes, respecting people's personal freedom, and generating tax revenue for state and local governments are key reasons for their support.
Marijuana legalization supporters are less likely to say that increasing the drug's safety through government regulation or believing that marijuana is not harmful are very important reasons they hold the opinion they do.
The results are based on a May 15-30 Gallup poll that sought to explore some of the reasons behind Americans' opinions for, or against, making marijuana legal. Gallup has documented a sharp increase in the percentage of Americans favoring legal marijuana in the past decade, from 44% in 2009 to 64% in the current survey. Gallup has measured support as high as 66% in an October 2018 update. In 1969, the first time Gallup polled on the issue, just 12% were in favor of legalizing marijuana.
For the most part, different subgroups of marijuana legalization advocates are similar in their stated reasons for supporting legal marijuana. One modest difference concerns the importance of tax revenue for state and local governments, something that 63% of male supporters versus 50% of female supporters regard as very important.
The roughly one-third of Americans who oppose legalization were asked to say how important each of six factors is to their position on the issue. Foremost among these is the possibility of increased car accidents involving drivers who use marijuana -- 79% say this is a very important reason they oppose legalizing the drug.
Additionally, at least six in 10 opponents rate three other factors as very important reasons behind their objections: the possibility that marijuana users would try stronger and more addictive drugs; the potential for marijuana usage to increase; and that legalizing marijuana would not benefit society much. A slim majority of opponents cite its potential harm to users....
The most compelling reason for legalization, according to those who hold that position, is the help it gives to those who use it for medicinal purposes. Also, supporters tend to point to the possible benefits legal pot would have on law enforcement, state and local governments, and personal freedom. A "lack of harm" for users does not appear to a be a major reason why people want marijuana legalized.
Opponents, though smaller in number, point more to the societal risks, including those related to car accidents and marijuana users trying more potent drugs that likely would have a greater societal cost for those who become addicted.
Though these poll results are interesting (and not all that surprising), it is somewhat disappointing that the questions exploring support for and opposition to marijuana reform were not more refined. In particular, given concerns about the "war on drug" and its racial skew, I would have liked to seen more "support" questions focused on various criminal justice reform concerns. Similarly, the opposition questions did not explore widespread concerns about increasing youth access to and use of marijuana. Some of the existing questions get near to these topics, but I suspect more or more refined questions would have impacted the outcomes.
Thursday, June 6, 2019
The leading national group opposed to modern marijuana reform, Smart Approaches to Marijuana (SAM), has this big new report titled "Lessons Learned from State Marijuana Legalization" Here is the short "Executive Highlights" from the start of the report:
Today’s highly potent marijuana represents a growing and significant threat to public health and safety, a threat that is amplified by a new marijuana industry intent on profiting from heavy use.
State laws allowing marijuana sales and consumption have permitted the marijuana industry to flourish, and in turn, the marijuana industry has influenced both policies and policy-makers. While the consequences of these policies will not be known for decades, early indicators are troubling.
This report, reviewed by prominent scientists and researchers, serves as an evidence-based guide to what we currently observe in various states. We attempted to highlight studies from all the “legal” marijuana states (i.e., states that have legalized the non-medical use of marijuana). Unfortunately, data does not exist for several “legal” states, and so this document synthesizes the latest research on marijuana impacts in states where information is available.
Disappointingly, this report does not cover data comprehensively on any single topic from any one state nor does it effectively detail similar data across a number of states. Rather, as seems common with SAM reports, this latest report focuses on the most troublesome data from a few states to make the case that marijuana reform is creating big problems. In this way, the report serves as a good review of some of the strongest "data talking points" against marijuana reform, but it does not really provide a sound basis to reach sound conclusions about what lessons should be learned from modern marijuana reforms.
June 6, 2019 in History of Marijuana Laws in the United States, Recreational Marijuana Commentary and Debate, Recreational Marijuana Data and Research, Recreational Marijuana State Laws and Reforms, Who decides | Permalink | Comments (0)
Tuesday, June 4, 2019
Spotlighting former congressional leader John Boehner (and his cohorts) following the marijuana money
The New York Times has this notable new account of the work of the former US House Speaker as salesman for marijuana reform. The front-page lengthy piece, headlined "John Boehner: From Speaker of the House to Cannabis Pitchman," is an interesting read and here are a few excerpts:
John A. Boehner, the former speaker of the House, once stood second in line for the presidency and staunchly against legalized marijuana. Now you can find the longtime Republican standing before a wall-size photo of the Capitol, making an online infomercial pitch for the cannabis industry. “This is one of the most exciting opportunities you’ll ever be part of,” Mr. Boehner says in an endlessly streaming video for the National Institute for Cannabis Investors. “Frankly, we can help you make a potential fortune.”
Mr. Boehner’s pro-weed epiphany coincides with the prospect of a payday as high as $20 million from the industry he once so vigorously opposed. He sits on the board of Acreage Holdings, a marijuana investment firm whose sale to a cannabis industry giant hinges on Mr. Boehner’s ability to persuade Congress and the federal government to legalize, or at least legitimize, marijuana.
The chain-smoking, merlot-sipping, former 12-term congressman from Ohio says he had never lit a joint in his life when he and the former Massachusetts governor William F. Weld, now a Republican candidate for president, joined Acreage’s board last year. This year, Acreage announced plans to sell itself to Canopy Growth, a Canadian company that is the biggest cannabis holding in the world. The deal, worth around $3 billion, based on current stock prices for both Acreage and Canopy, would create an $18 billion behemoth, industry analysts say. Buried deep in a financial filing from Nov. 14, 2018, is Acreage’s disclosure that the two men each hold 625,000 shares in the company, which if sold after the company’s sale to Canopy would net them a fortune.
Representative Earl Blumenauer, Democrat of Oregon and a founder of the Congressional Cannabis Caucus, said he saw Mr. Boehner at a dinner on Capitol Hill the day he joined Acreage. “I said, ‘John, where were you when we needed you?’ And he said, ‘I’ve evolved,’” Mr. Blumenauer recalled in an interview, imitating Mr. Boehner’s smoky baritone. (Mr. Boehner had made a similar statement on Twitter earlier that day.)
“He’s nothing if not entrepreneurial,” Mr. Blumenauer said. “The more the merrier.” But there is a catch. The takeover will not happen without substantial changes in marijuana policy, leaving it up to Mr. Boehner and his team of lobbyists to work their magic in Washington.
Mr. Boehner declined to be interviewed for this article. Terry Holt, a spokesman for the National Cannabis Roundtable, which Mr. Boehner founded in February, declined to speculate on Mr. Boehner’s potential income from the sector. Mr. Boehner “sees an investment opportunity in cannabis,” Mr. Holt said. Citing statistics suggesting most Americans favor “some kind of marijuana reform,” he added, “Who wouldn’t want to be involved?”
A slew of former lawmakers agree. Among those who have signed on in recent months to represent the weed industry are former Senator Tom Daschle of South Dakota, a longtime Democratic leader in the Senate; former Representative Dana Rohrabacher, Republican of California; former Representative Joseph Crowley, Democrat of New York; and former Representative Carlos Curbelo, Republican of Florida....
In 2016, [Boehner] joined Squire Patton Boggs, successor to the marquee Washington law and lobbying firm, as a “strategic adviser.” About the same time, Mr. Boehner, who once handed out campaign checks from the tobacco industry to lawmakers on the House floor, joined the board of the tobacco giant Reynolds American, makers of his favorite Camel brand.
Reynolds directors with his profile earn roughly $400,000 a year, and Mr. Boehner holds other board seats, too, Mr. Holt said. Combined with a pension derived from his $223,000 annual congressional salary, Mr. Boehner likely earns a seven-figure retirement income, even without the potential Acreage windfall.
Mr. Boehner and Mr. Weld joined Acreage’s board in April 2018, and together issued a statement: “We both believe the time has come for serious consideration of a shift in federal marijuana policy.” For evidence, “We need to look no further than our nation’s 20 million veterans, 20 percent of whom, according to a 2017 American Legion survey, reportedly use cannabis to self-treat PTSD, chronic pain and other ailments,” they said, denouncing “the refusal of the V.A. to offer it as an alternative” to opioids.
Chanda Macias, the National Cannabis Roundtable’s first vice chairwoman and the owner and general manager of the National Holistic Health Center medical marijuana dispensary in Washington, said that she had seen more than 10,000 patients who suffer from a lack of research, education and access to medical marijuana. “This is not about Boehner,” Ms. Macias added, “this is about saving lives.”
Friday, May 31, 2019
Illinois poised to become first big state to legalize adult use/recreational marijuana via traditional legislation
A couple of big states on the east coast, New Jersey and New York, saw efforts this year to fully legalize marijuana via traditional legislation falter. But it seems that the biggest midwestern state, Illinois, got this done this legislative session as reported in this local article:
A recreational marijuana legalization bill will soon land on Gov. J.B. Pritzker’s desk after the Illinois House on Friday voted to pass the comprehensive measure.
The Illinois House voted 66-47 after more than three hours of debate. The Illinois Senate on Wednesday cleared the measure. The governor issued a statement applauding the bill’s passage and pledging to sign it. “The state of Illinois just made history, legalizing adult-use cannabis with the most equity-centric approach in the nation,” Pritzker said. “This will have a transformational impact on our state, creating opportunity in the communities that need it most and giving so many a second chance.”
While there are giant swaths of criminal justice and social equity reforms attached to the measure — including giving a second chance to thousands of people convicted of marijuana possession — practically speaking it will allow Illinois residents over 21 to buy cannabis from licensed dispensaries as soon as Jan. 1.
If signed into law, Illinois will become the first state to approve cannabis sales through the Legislature, instead of a ballot measure. There are laws regulating and taxing cannabis in nine states. In Vermont and Washington, D.C., cannabis possession and cultivation is legal but sales are not regulated.
The measure would also allow Illinoisans over 21 years old to possess 30 grams, or just over an ounce of cannabis flower, and 5 grams, or less than a quarter-ounce, of cannabis concentrates such as hash oil. Additionally, Illinoisans would be able to carry up to a half-gram of edible pot-infused products.
“It is time to hit the reset button on the war on drugs,” bill sponsor state Rep. Kelly Cassidy, D-Chicago, said during the debate. “What is before us is the first in the nation to approach this legislatively, deliberately, thoughtfully, with a eye toward repairing the harm and the war on drugs. We have an opportunity today to set the gold standard for a regulated market that centers on equity and repair.”...
Others weren’t convinced. State Rep. Mary Flowers, D-Chicago, said “the reset button is broken.” “The fact of the matter is nothing in this bill addresses the harm that’s been done to our community,” Flowers said. “Our community is still being used for people to make a profit and get rich and give nothing to the community.”
Amid opposition, some initiatives in the initial measure, which was filed in early May, were scaled back. A House committee this week approved changes that include allowing only medical marijuana patients to have up to five plants in a home. There were also changes made within the expungement provisions, which would have initially automatically expunged hundreds of thousands of marijuana possession convictions.
Now, convictions dealing with amounts of cannabis up to 30 grams will be dealt with through the governor’s clemency process, which does not require individuals to initiate the process. For amounts of 30 to 500 grams, the state’s attorney or an individual can petition the court to vacate the conviction.
The updated language means those with convictions for cannabis possession convictions under 30 grams can get pardoned by the governor. States attorneys would then be able to petition the court to expunge the record. A judge would direct law enforcement agencies and circuit court clerks to clear their record. This only applies to those convicted with no other violent crime associated with the charge. And it only applies for convictions that have taken place when the bill takes effect on Jan. 1....
Designed to address concerns about impaired driving, the measure would also add a DUI Task Force led by Illinois State Police to examine best practices. Those would include examining emergency technology and roadside testing.
Sales from recreational marijuana is expected to bring in $57 million in this year’s budget and $140 million next year, sponsors have said. It should eventually rise to $500 million a year once the program is fully running.
Thursday, May 30, 2019
Split Second Circuit panel gives small victory to medical marijuana users while turning away their high-profile court challenge to Schedule I placement
I have noted in a number of prior posts linked below the notable lawsuit seeking to ensure legal access to medical marijuana that was filed in federal district court in New York in July 2017 (first discussed in this post.) In February of 2018, as noted in this post, US District Judge Alvin Hellerstein dismissed the suit, ruling the litigants had "failed to exhaust their administrative remedies” while concluding that "it is clear that Congress had a rational basis for classifying marijuana in Schedule I." In response to that ruling, I said "plaintiffs in this suit could appeal this dismissal to the US Court of Appeals for the Second Circuit, and doing so would likely keep the case in the headlines [but] I am not optimistic it would achieve much else."
In fact, an appeal was brought to the Second Circuit, and it did achieve something: an interesting split panel ruling that provides an interesting small victory to the plaintiffs despite ultimately failing to provide an real relief. Specifically, the majority opinion authored by Judge Guido Calabresi in Washington v. Barr, No. 18-859 (2d Cir. May 30, 2019) (available here), gets started this way:
This is the latest in a series of cases that stretch back decades and which have long sought to strike down the federal government’s classification of marijuana as a Schedule I drug under the Controlled Substances Act (CSA), 2 U.S.C. § 801 et seq. See, e.g., Krumm v. Drug Enforcement Admin., 739 F. App’x 655 (D.C. Cir. 2018) (mem.); Ams. for Safe Access v. Drug Enforcement Admin., 706 F.3d 438 (D.C. Cir. 2013); Alliance for Cannabis Therapeutics v. Drug Enforcement Admin., 15 F.3d 1131 (D.C. Cir. 1994) (mem.). The current case is, however, unusual in one significant respect: among the Plaintiffs are individuals who plausibly allege that the current scheduling of marijuana poses a serious, life‐or‐death threat to their health. We agree with the District Court that Plaintiffs should attempt to exhaust their administrative remedies before seeking relief from us, but we are troubled by the Drug Enforcement Administration (DEA)’s history of dilatory proceedings. Accordingly, while we concur with the District Court’s ruling, we do not dismiss the case, but rather hold it in abeyance and retain jurisdiction in this panel to take whatever action might become appropriate if the DEA does not act with adequate dispatch.
Judge Jacobs dissents from the panel's failure to just dismiss the lawsuit, and his opinion starts this way:
The plaintiffs seek a declaration that the classification of marijuana as a Schedule 1 substance is unconstitutional because it does not reflect contemporary learning regarding the drug’s medicinal uses. I agree with the District Court that this case must be dismissed for failure to exhaust administrative remedies in the Drug Enforcement Agency (“DEA”). The majority opinion does not actually disagree, though it seems to treat lack of jurisdiction as a prudential speed bump. I dissent from the majority opinion’s decision to hold the case in abeyance so that we may turn back to it if, at some future time, we get jurisdiction.
Prior related posts:
- Latest effort to take down federal marijuana prohibition via constitutional litigation filed in SDNY
- "Colorado girl suing U.S. attorney general to legalize medical marijuana nationwide"
- Could a high-profile lawsuit help end federal marijuana prohibition?
- Mixed messages from US District Judge hearing legal challenge to federal marijuana prohibition
- Federal judge dismisses high-profile suit challenging marijuana's placement on Schedule 1 under the Controlled Substances Act
May 30, 2019 in Court Rulings, Federal Marijuana Laws, Policies and Practices, History of Marijuana Laws in the United States, Medical Marijuana Commentary and Debate, Who decides | Permalink | Comments (0)
Wednesday, May 29, 2019
Last year, an intermediate appellate court in Arizona ruled that a medical marijuana patient could still be criminal prosecuted for possession of hashish because, in the court's view, the Arizona Medical Marijuana Act retained a distinction between cannabis and marijuana and preserved the criminality of the former. But yesterday, in Arizona v. Jones, No. CR-18-0370-PR (Ariz. May 28, 2019) (available here), the Arizona Supreme Court ruled unanimously that "AMMA’s definition of marijuana includes both its dried-leaf/flower form and extracted resin, including hashish." Here is an excerpt from the tail end of the opinion:
AMMA appeared on the 2010 ballot as Proposition 203. The accompanying ballot materials stated Proposition 203’s purpose was to “protect patients with debilitating medical conditions . . . from arrest and prosecution” for their “medical use of marijuana.” Ariz. Sec’y of State, 2010 Publicity Pamphlet 73 (2010). Proposition 203 was intended to allow the use of marijuana in connection with a wide array of debilitating medical conditions, including “cancer, glaucoma, . . . amyotrophic lateral sclerosis, Crohn’s disease, [and] agitation of Alzheimer’s disease,” including “relief [from] nausea, vomiting and other side effects of drugs” used to treat debilitating conditions. Id. It is implausible that voters intended to allow patients with these conditions to use marijuana only if they could consume it in dried-leaf/flower form. Such an interpretation would preclude the use of marijuana as an option for those for whom smoking or consuming those parts of the marijuana plants would be ineffective or impossible. Consistent with voter intent, our interpretation enables patients to use medical marijuana to treat their debilitating medical conditions, in whatever form best suits them, so long as they do not possess more than the allowable amount....
We hold that the definition of marijuana in § 36-2801(8) includes resin, and by extension hashish, and that § 36-2811(B)(1) immunizes the use of such marijuana consistent with AMMA. We reverse the trial court’s ruling denying Jones’s motion to dismiss, vacate the court of appeals’ opinion, and vacate Jones’s convictions and sentences.
Wednesday, May 22, 2019
The title of this post is the title of this new article authored by Joelle Anne Moreno and now available via SSRN. Here is its abstract:
Weed, herb, grass, bud, ganja, Mary Jane, hash oil, sinsemilla, budder, and shatter. Marijuana – whether viewed as a medicine or intoxicant – is fast becoming a part of everyday life, with the CDC reporting 7,000 new users every day and the American market projected to grow to $20 billion by 2020. Based on early campaign rhetoric, by that same year the U.S. could have a pro-marijuana president.
Despite its growing acceptance and popularity, marijuana remains illegal under federal law. Like heroin, LSD, and ecstasy, marijuana is a DEA Schedule I drug reflecting a Congressional determination that marijuana is both overly addictive and medically useless.
So what is the truth about pot? The current massive pro-marijuana momentum and increased use, obscures the fact that we still know almost nothing about marijuana’s treatment and palliative potential. Marijuana’s main psychoactive chemical is THC; but it also contains over 500 other chemicals with unknown physiological and psychological effects that vary based on dosage and consumption method. Medical marijuana may be legal in 32 states and supported by 84% of Americans, but federal constraints shield marijuana from basic scientific inquiry. This means that lawmakers and voters are enthusiastically supporting greater access to a drug without demanding critical scientific data. For policymaking purposes, this data should include marijuana’s short and long-term brain effects, possible lung and cardiac implications, chemical interactions with alcohol and other drugs, addiction risks, pregnancy and breast-feeding concerns, and the effects of secondhand smoke.
This Article treats marijuana as a significant contemporary science and law problem. It focuses on the fundamental question of regulating a substance that has not been adequately researched. The Article examines the extant scientific data, deficiencies, and inconsistencies and explains why legislators should not rely on copycat laws governing alcohol or prescription narcotics. It also explores how marijuana’s hybrid federal (illegality)/state (legality) raises compelling theoretical and practical Constitutional questions of preemption, the anti-commandeering rule, and congressional spending power. Marijuana legalization has, thus far, been treated as a niche academic concern. This approach is short-sighted and narrowminded. Marijuana regulation implicates the reach of national drug policy, the depth of state sovereignty, and the shared obligation to ensure the health and safety of our citizenry.
May 22, 2019 in Campaigns, elections and public officials concerning reforms, Federal Marijuana Laws, Policies and Practices, History of Marijuana Laws in the United States, Medical Marijuana Commentary and Debate, Political perspective on reforms, Recreational Marijuana Commentary and Debate, Who decides | Permalink | Comments (1)
Monday, May 20, 2019
The title of this post is the title of this paper recently posted to SSRN authored by Tyler G. Aust, who just recently graduated from The Ohio State University Moritz College of Law. This paper is now the four of what will be an on-going series of student papers supported by Drug Enforcement and Policy Center. (The first three papers in this series are linked below.) Here is this latest paper's abstract:
The proliferation of legal marijuana foretells an uncertain future for businesses that implement zero-tolerance drug policies. In states where recreational marijuana is legal, businesses still have the power to enforce drug policies through employment contracts. That changed in Maine, where state law prohibits employers from making adverse employment decisions based solely on an employee’s off-duty use of marijuana. As legalization efforts sweep across the Midwest, it is unclear whether other states will follow Maine’s model. Some businesses have already relaxed pre employment marijuana testing amid labor shortages. To prepare for the future, employers should revise their drug policies to distinguish between on-duty and off-duty marijuana consumption and allow employees to use marijuana outside of the workplace.
Prior student papers in this series:
- "The Canna(business) of Higher Education"
- "Marijuana Banking in New York and Around the US: 'Swim at Your Own Risk'"
- "Intellectual Property Survey: Cannabis Plant Types, Methods of Extraction, IP Protection, and One Patent That Could Ruin It All"
There is so much media coverage of so many marijuana related issues that I barely have time to keep up with my reading, let alone blog about all the interesting stories. (E.g., I keep meaning to blog about the New York Times Magazine's CBD cover story.) But in the last day, I saw three lengthy and connected stories that relate to the intersection of marijuana reform, politics and social justice that seems to have come now to define the realities and challenges of this space. The headlines of the three pieces help capture the themes:
From the AP, "Pot ‘legalization 2.0’: Social equity becomes a key question"
From Politico, "How Democrats are failing on legalized marijuana"
In addition to recommending all these pieces, I will seek to summarize them by just saying it has always been clear to me that effective and sound legal reform in this space is very, very hard and calls for lots and lots of folks working very, very hard to get it as right as possible from the outset and then continuing to work very, very hard to assess and refine reform regimes.
May 20, 2019 in Criminal justice developments and reforms, History of Marijuana Laws in the United States, Race, Gender and Class Issues, Recreational Marijuana Commentary and Debate, Who decides | Permalink | Comments (0)
Tuesday, May 14, 2019
My east coast roots (and bias?) has long led me to look at the New York Times as the "paper of record" in so many ways (and that thinking led me to view as so important the 2014 New York Times editorial calling for the legalization of marijuana). But the biggest developments in the marijuana reform space have taken place in other regions, and so other papers, especially the Denver Post and the Boston Globe, have been much more at the forefront of marijuana coverage.
But the Gray Lady seems to be keeping pace with marijuana developments these days, and some headlines from distinct section of the paper this past week highlights all the angles the paper is now covering:
From the local section, "Marijuana Legalization Hits a Wall: First in New Jersey, Then in New York"
From the U.S. section,"Attorneys General From 33 States Urge Pot Banking Reform"
From the "Mind" section, "The Stoner as Gym Rat"
From the "Style" section, "Design’s New Leaf"
And, interestingly, the NYT is also now soliciting tales to tell via this "Reader Center" quesy: "How Has Colorado’s Legalization of Marijuana Affected You? Help us better understand how Coloradans are adapting to their state’s legalization of pot."
Of course, the Gray Lady has not quite yet turned into Marijuana Moment. But it is still interesting to see the stories it is deciding to cover in this space, and encouraging that they are eager to inquire further.
Sunday, May 12, 2019
As noted in this post, in January I had the opportunity to participate in an exciting cannabis industry panel discussion, co-sponsored by the Ohio State Drug Enforcement & Policy Center (DEPC), under the heading "Cannabiz Roundtable." This coming week, on Thursday, May 16 and as detailed here, another set of cannabis industry participants are part of another DEPC discussion this time titled "Cannabiz Roundtable: Industry Diversity & Legislative Updates."
The event is described at this link, where one can find this event description:
The legal landscape of the cannabis industry continues to change both at the state and federal level, creating continuous challenges and opportunities for entrepreneurs in Ohio. At the same time, the cannabis industry is facing a challenge of ensuring that it reflects the diversity of our community and that communities that have been disproportionately affected by the War on Drugs benefit from opportunities in the legal industry. Please join us for our second Business of Cannabis Roundtable where we will host two panels discussing both issues.
Building Industry Diversity
As in many other states, the cannabis industry in Ohio is challenged with ensuring that it reflects the diversity of its community. Despite increased attention among the industry professionals and government entities alike, companies continue to struggle with recruiting, training and retaining a diverse workforce. Please join our panel of industry professionals as they discuss their own experience of entering this new industry, resources that are available for training and recruitment and strategies for building a diverse industry.
Our second panel will focus on legislative and regulatory updates in respect to Ohio’s medical marijuana program and Ohio’s treatment of hemp and CBD. Given the recent changes in the federal law, our panel of experts will discuss what changes are afoot in Ohio and how will these changes affect the cannabis industry.
May 16th, 2019, starting at 4pm, at the Ohio Union round Meeting Room (3rd Floor)
Wednesday, May 8, 2019
Despite early vote counts suggesting a close defeat of a Denver initiative to decriminalize hallucinogenic psilocybin mushrooms, the final vote count showed that the initiative squeaked out a victory. This local article, headlined "Denver first in U.S. to decriminalize psychedelic mushrooms," provides the details:
Denver is poised to become the first city in the nation to effectively decriminalize psychedelic mushrooms.
After closing an early vote deficit Tuesday night and early Wednesday, final unofficial results posted late in the afternoon showed a reversal of fortune — with Initiative 301 set to pass narrowly with 50.6 percent of the vote. The total stands at 89,320 votes in favor and 87,341 against, a margin of 1,979. The Denver Elections Division will continue accepting military and overseas ballots, but typically those numbers are small. Results will be certified May 16....
Denver’s vote has attracted national attention. While efforts are afoot to get psilocybin-related measures on the ballot in Oregon and California in 2020, Denver hosted the first-ever U.S. popular vote on the matter, according to organizers. An earlier effort in California last year failed to qualify for the ballot.
Though Initiative 301 attracted no organized opposition, critics of Colorado’s legalization of marijuana lamented the prospect of Denver blazing yet another trail they see as misguided and potentially harmful. The measure essentially tells police to look the other way on adult psilocybin use....
Supporters extolled emerging research showing potential health benefits with psychedelic mushrooms. The measure likely was put over the top by younger voters, who tend to cast their ballots closer to or on Election Day, even though all registered voters receive their ballots in the mail about three weeks earlier.
Last fall, the U.S. Food and Drug Administration granted psilocybin “breakthrough therapy” designation for its potential to help with treatment-resistant depression, a status that speeds up the development and review process for a medicine containing the substance.
As written, I-301 directs police via ordinance to treat enforcement of laws against possession of psilocybin mushrooms as their lowest priority.
It’s similar to decriminalization measures approved by Denver voters for marijuana years before Colorado’s Amendment 64 won statewide approval....
Psychedelic mushrooms still would remain illegal to buy, sell or possess, with the latter crime a felony that carries a potential punishment of up to a year in prison and a fine. But Initiative 301 backers hope to lower the risk users face of getting caught with mushrooms.
Past marijuana efforts are instructive, though. Denver voters signed off on decriminalization measures in 2005 and 2007, but that didn’t stop police from enforcing the law — though drug law-liberalization advocates say the public discussion prompted by the ballot initiatives helped pave the way for statewide legalization in 2012.
Tuesday, May 7, 2019
As reported in this article, headlined "Denver Measure to Decrim Magic Mushrooms Trailing in Returns," it appears that voters in the Mil High City are not quite ready to pioneer a new front in the drug reform movement. Here are the basics:
A Denver initiative that would have made it the first city in the country to decriminalize hallucinogenic psilocybin mushrooms was trailing in the polls as early results were announced Tuesday night. The measure was losing, 54% to 45%, in early election returns on Tuesday night. As of 8:30 p.m., Initiative 301 was down by 54% to 45%, a margin of more than 8,600 votes.
The measure would have decriminalized possession and use of the drug — which remains classified as a Schedule I substance by the U.S. government — within city limits, which advocates said would have opened up the potential health benefits of hallucinogenics.
Research from Johns Hopkins University found that psilocybin showed benefits for depression and anxiety; other research has shown that it showed benefits for addiction, cluster headaches and even post-traumatic stress disorder.
Kevin Matthews, a stay-at-home dad and campaign manager for Decriminalize Denver, the campaign for Initiative 301, spoke to supporters just after results poured in and offered an optimistic message. “This is not over yet,” he said. “We all know that this goes way beyond Denver,” he added. “Right now this thing is a coast-to-coast movement.”...
Attention will now turn to other progressive cities. Advocates in Oakland, CA, are working on their own psychedelic decriminalization ballot measure, and a campaign in Oregon seeks to put a magic mushroom measure before voters in the 2020 election.
Supporters were hopeful that Denver, which became the first city to decriminalize cannabis in 2005, could be the standard bearer for hallucinogenic legalization as well. The 2005 vote eventually led to the state legalizing recreational marijuana seven years later, setting off a wave of legalization across the country.
Wednesday, May 1, 2019
The question in the title of this post is prompted by this notable story out of Boston headlined "Harvard, MIT share $9 million gift to study marijuana's health effects." Here are the interesting details:
An investor in the cannabis industry has donated $9 million to Harvard and MIT to study the drug’s health effects, in what the institutions describe as the largest private gift to support marijuana research in the United States. The Broderick Fund for Phytocannabinoid Research, announced Tuesday morning, will be shared equally by Harvard Medical School and the Massachusetts Institute of Technology, with the goal of filling vast gaps in the understanding of how marijuana affects the brain and behavior.
“The lack of basic science research enables people to make claims in a vacuum that are either anecdotal or based on old science,” said the donor, Charles R. “Bob” Broderick, an alumnus of both universities. “For generations we haven’t been able to study this thing for various sorts of societal reasons. That should end now, as well as the prohibitions that are falling around the world.”
Broderick has invested heavily in the booming marijuana business, starting in Canada in 2015 and more recently the United States, through his family-run Uji Capital. Although Broderick stands to profit if the studies find benefits from marijuana, the universities and the researchers said the donor will have no say in the work process or its results. They also pledged to publish their findings even if they find marijuana doesn’t help or causes harm.
Broderick recalled the first time he raised the idea of funding cannabis research with a Harvard development officer: “There was silence on the other end. Then she said, ‘I don’t think we do it.’ And I said, ‘That’s the problem.’ ” The official soon called back to say that Harvard researchers studying brain chemicals would be interested in examining marijuana’s effects.
Dr. Igor Grant, a longtime California marijuana researcher who is not involved with the Harvard-MIT project, said the grant “will really let them move forward with research that has been difficult to fund.”
“The work in this area has been very, very slow coming,” said Grant, director of the Center for Medicinal Cannabis Research at the University of California San Diego.
“This is exactly the type of research we need,” said Dr. Peter Grinspoon, a Massachusetts primary care doctor and board member of Doctors for Cannabis Regulation, a group promoting legalization and regulation of marijuana. Whether for or against marijuana, Grinspoon said, “Everybody wants more research.” The marijuana studies to date vary in quality, often have conflicting results, and typically involve either purified extracts or smoked marijuana — not the gummies, cookies, vapor, oils, or highly potent buds that people consume today....
Until recently researchers could work only with marijuana grown at a federal farm in Mississippi, whose plants are less potent than those purchased at dispensaries in states where the drug is legal. But John Gabrieli, a professor of brain and cognitive sciences at MIT and one of the grant recipients, said “a fast-changing regulatory environment” is allowing access to better material.
The MIT researchers intend to use extracts from the plants to tease out the effects of marijuana in people with schizophrenia — about half of whom are heavy cannabis users, Gabrieli said. The researchers want to pursue intriguing evidence that a component in marijuana known as tetrahydrocannabinol, or THC, improves cognitive function in people with schizophrenia. They will look at how THC as well as another key component — cannabidiol, or CBD — affect cognition alone and in combination.
Another MIT researcher will study how chronic exposure to THC and CBD may alter the cell types implicated in schizophrenia, potentially shedding light on why teens who use cannabis are at greater risk of developing schizophrenia and why the drug may be more dangerous for teens than adults.
Other studies at MIT will examine whether marijuana ingredients can help people with autism and with Huntington’s disease, and will study the effects of cannabis ingredients on attention and working memory. It’s been “incredibly hard” to get funding for marijuana research, Gabrieli said. “It’s been illegal all over the place until very recently. Without the philanthropic boost, it could take many years to work through all these issues.”
At Harvard, the $4.5 million gift establishes the Charles R. Broderick Phytocannabinoid Research Initiative, involving some 30 basic scientists and clinicians at the medical school and its affiliated hospitals. The Harvard team plans to study the effects of marijuana ingredients on brain cell function and the connections between brain cells, testing purified ingredients on mice and rats.
Researchers at Harvard have been studying natural brain chemicals known as endocannabinoids, which are involved in a variety of functions, including memory, appetite, and stress response. The grant will enable them to expand that research to encompass cannabinoids derived from plants. “Marijuana has about 100 different cannabinoid compounds. We understand very little about the specific effects of each of them on the nervous system,” said Bruce Bean, Harvard neurobiology professor and one of the project’s researchers....
The research, however, is funded by someone who could profit if the findings are favorable or lose money if new dangers are discovered. Could knowing this somehow, even unconsciously, bias the results? Josephine Johnston, director of research at the Hastings Center, a think tank concerned with bioethics, said such conflicts of interest are commonplace. “In a pure world, you wouldn’t have a situation like this. But it’s pretty much a fact of life of biomedical research in the United States that you have interested parties funding research,” said Johnston, co-editor of a book on conflicts of interest in biomedical research. Institutions can enact safeguards to ensure both that the research is unbiased and that it’s perceived as trustworthy.
Both MIT and Harvard said they have such policies in place, requiring that gifts come without strings attached and that researchers have control over their work and its publication. Grant, the California marijuana researcher, agreed that conflict of interest is an important concern. But, he added, if people profiting from the marijuana boom invest in science, “maybe that’s not a bad thing. They could just as easily buy yachts or do something else.”
Because I am a kind of marijuana researcher (focused on law and social science, rather than medical science), I realize I have a bias when suggesting that everyone involved in the marijuana industry ought to be funding academic marijuana research. Also, as a director of the Drug Enforcement and Policy Center at The Ohio State University, I am sensitive to the concern that research funded by the marijuana industry or investors carries real conflict risks that can come with any private funding of public research.
All that said, this article helps highlight just some of the many reasons why a lot more private funding (and a lot more public funding) is needed for all sorts of marijuana research. There are many times I end up feeling truly overwhelmed by all the important research questions that arise in this space and all the formal and informal barriers to conducting all the needed research. And especially with so many legal and social changes in this space, this period seems like an "all hands on deck" moment. And I do not think it is misguided to believe that everyone involved in the marijuana industry and especially its investors ought to be swabbing the deck as best they can.
May 1, 2019 in Business laws and regulatory issues, Medical community perspectives, Medical Marijuana Data and Research, Recreational Marijuana Data and Research, Who decides | Permalink | Comments (0)
Monday, April 29, 2019
The title of this post is the title of this paper just posted to SSRN authored by Jordan Hoffman, who is a student at The Ohio State University Moritz College of Law. This is the second of what will be an on-going series of student papers supported by Drug Enforcement and Policy Center. (The first paper in the series was authored by Shelby Slaven under the title "The Canna(business) of Higher Education.")
Here is the abstract of this new paper on marijuana banking:
Today, banking in any way relating to marijuana is a violation of federal law. Conflicting laws and guidance from the federal and state governments threatens the welfare and success of a billion-dollar industry. Analyzing the current marijuana banking laws, regulations, and practices in New York and around the US provides a glimpse into an industry suffocating from public pressures and overpowering economic tides. To protect and uphold the integrity of our government and the agencies it deems controlling, the federal government must reform marijuana banking.
April 29, 2019 in Business laws and regulatory issues, Federal Marijuana Laws, Policies and Practices, History of Marijuana Laws in the United States, Medical Marijuana Commentary and Debate, Recreational Marijuana Commentary and Debate, Who decides | Permalink | Comments (0)
Friday, April 12, 2019
The title of this post is the title of this paper just posted to SSRN and authored by Shelby Slaven, who is a student at The Ohio State University Moritz College of Law. Here is the paper's abstract:
While the idea of legalizing cannabis for adult use is gaining on acceptance among the public, the past and current policies on both, the state and federal level, have resulted in dearth of research on the efficacy of cannabis for therapeutic purposes as well as possible societal and health consequences of recreational use. Institutes of higher education are best positioned not only to reform research on the substance, but to train a generation of cultivators, distributors, and healthcare professionals, and while doing so address some of the historical harms perpetrated by the policies of the War on Drugs. Students are seeking out ways to capitalize on a growing market and remedying past discrimination should be a top priority. This paper first provides an overview of cannabis legalization as it stands today, the political efforts that got it here, and those that will move it forward. It then discusses institutes of higher education and the efforts to bring cannabis into the classroom. Lastly, this paper argues that Historically Black Colleges and Universities can provide education, training, and a foot in the door for Black individuals who have suffered harsher criminal penalties in the name of the war on crime.
April 12, 2019 in Business laws and regulatory issues, Employment and labor law issues, History of Marijuana Laws in the United States, Medical Marijuana Commentary and Debate, Race, Gender and Class Issues, Recreational Marijuana Commentary and Debate, Who decides | Permalink | Comments (0)
I am very sad that presentations in my my Marijuana Law, Policy & Reform seminar have wrapped up, but that reality gives me a bit more time and space here to catch up on the marijuana law, policy and reform stories that most catch my eye. One such important story that I missed a few weeks ago comes here from Stateline under the headline "African-Americans Missing Out on Southern Push for Legal Pot." I recommend the extended article in full, and here are some excerpts:
Medical cannabis laws typically lay out the conditions for which the drug may be prescribed. But the laws in Arkansas and Florida — the only Southern states that have legalized medical cannabis — don’t cover sickle cell disease, which causes acute pain and disproportionately affects African-Americans. The bills advancing in Tennessee and Kentucky also exclude that condition. Three states that have legalized medical but not recreational cannabis — Connecticut, Ohio and Pennsylvania — allow sickle cell disease patients to use it....
Black legalization advocates also fear that even if medical cannabis becomes legal, white politicians won’t regulate licensing and permitting in a way that ensures equitable opportunities for people of color. “Without that, it’ll be more of the same,” said Dr. Felecia Dawson, a board-certified physician who closed her Georgia-based OB-GYN practice to focus on advocating for medical cannabis. “Legislators will keep people of color ... from the benefits of cannabis.”
Nationally, research suggests that medical marijuana use is more common among whites with high incomes, perhaps in part because of the long history of racial disparity in drug enforcement....
Every Southern state by 2016 had legalized the treatment of a limited number of conditions using CBD oil. As public support increased, so did lawmakers’ willingness to expand the list of eligible conditions. But some conditions that affect minority populations at higher rates than white ones — such as sickle cell disease, which affects 73 in 1,000 African-Americans at birth compared with 3 whites, according to federal estimates — are not included in proposals currently making their way through several Southern statehouses.
In a 2017 hearing co-hosted by the Arkansas Medical Marijuana Commission, following a ballot initiative that had legalized medical cannabis, advocates wore “Diversity for All” T-shirts to emphasize the drug’s importance to minority residents. “We know that such diseases as hypertension, sickle cell, neuropathy and so on are more predominant in blacks,” Casey Caldwell, a black cannabis advocate, said at the hearing.
“It is safe to say that African-American communities would benefit the most,” she added. “In the past, pharmaceutical drugs have been priced so high that [we] have to make a decision whether or not they should eat or whether they should purchase medication.”
Those concerns echoed what Dee Dawkins-Haigler, a former Democratic Georgia representative who headed the state’s Black Caucus, said in 2015 about the initial absence of black people among the state’s 17 appointees to the Commission on Medical Cannabis. The Black Caucus eventually fought to get sickle cell disease added to the list of conditions eligible for CBD oil....
In Florida, black farmers initially cried foul at being shut out of the state’s multibillion-dollar cannabis trade over policies that required license holders to have operated for 30 straight years. According to Roz McCarthy, founder of the Florida-based advocacy group Minorities for Medical Marijuana, the state’s law lacked the teeth needed to ensure that medical cannabis license holders adhered to requirements to ensure diversity in hiring. A spokesperson for the Florida Department of Health said that state law “does not require medical marijuana treatment centers to report the race or ethnicity of its owners.”
McCarthy said, “We’re trying to push lawmakers to understand that they have the ability and the power to ensure exclusionary practices don’t happen. Barriers are there. But the opportunity to reduce barriers is also there.”
April 12, 2019 in Campaigns, elections and public officials concerning reforms, History of Marijuana Laws in the United States, Medical Marijuana Commentary and Debate, Medical Marijuana Data and Research, Medical Marijuana State Laws and Reforms, Race, Gender and Class Issues, Who decides | Permalink | Comments (0)
Monday, April 8, 2019
Regular readers will not be surprised to hear I am excited for the first of the last four student presentations planned for this coming week in my Marijuana Law, Policy & Reform seminar. Of course, I am excited about the work of all my students, but this wee we have a student focused on a topic on which I have done some writing, namely expungement practices. Here is how my student has summarized this topic, along with the background readings she has provided:
States that have chosen to decriminalize or legalize marijuana have, in most places, chosen to enact a specific marijuana expungement scheme within the bill that legalizes marijuana or separately. The expungement schemes offer a way for some to shed the hurtful effects of collateral consequences from a marijuana misdemeanor or felony.
As we come closer to legalizing marijuana on the federal level, the question of how to repair for the harms done by the War on Drugs and how best to expunge records will continue to be visited. The collateral consequences have consequences of their own and the War on Drugs helped fuel mass incarceration and racist policing practices. Robust and broad reforms will be needed to repair for the extensive damage to the criminal justice system, something marijuana legalization isn’t equipped to do wholly on its own. But the current expungement schemes, with filing fees, waiting periods and other hurdles, don’t set a good example as we head toward nationwide legalization.
Links to readings and background materials:
"Federal Collateral Consequences for Marijuana Convictions", Marijuana Policy Project paper explaining some of the federal collateral consequences resulting from marijuana convictions
"Drug offenders in American prisons: The critical distinction between stock and flow", Brookings piece by Jonathan Rothwell highlighting difference between stock and flow of drug prisoners which highlights that there are many more drug convictions than violent offense convictions.
"Why you can’t blame mass incarceration on the war on drugs", Vox article by German Lopez disputing Michelle Alexander’s "drug war" explanation for mass incarceration while explaining why the path to ending mass incarceration is complicated.
“Leveraging Marijuana Reform to Enhance Expungement Practices” by Douglas Berman
Links to Expungement Schemes:
Connecticut Bill - Bill for legalization in state's house judiciary committee
Friday, April 5, 2019
The question in the title of this post was my reaction of this news out of Congress as reported here by Marijuana Moment:
Reps. Earl Blumenauer (D-OR) and David Joyce (R-OH) filed the Strengthening the Tenth Amendment Through Entrusting States (STATES) Act, appearing alongside cosponsors Reps. Barbara Lee (D-CA) and Joe Neguse (D-CO) at a press conference. Sen. Cory Gardner (R-CO) and Elizabeth Warren (D-MA) filed the Senate version of the bill.... The legislation would amend the Controlled Substances Act to protect people complying with state legal cannabis laws from federal intervention, and the sponsors are hoping that the bipartisan and bicameral nature of the bill will advance it through the 116th Congress.
“I’ve been working on this for four decades. I could not be more excited,” Blumenauer told Marijuana Moment in a phone interview. While other legislation under consideration such as bills to secure banking access for cannabis businesses or study the benefits of marijuana for veterans are “incremental steps that are going to make a huge difference,” the STATES Act is “a landmark,” he said....
The congressman said it will take some time before the bill gets a full House vote, however. Rep. Jim McGovern (D-MA) recently suggested that the legislation would advance within “weeks,” but Blumenauer said it will “be a battle to get floor time” and he stressed the importance of ensuring that legislators get the chance to voice their concerns and get the answers they need before putting it before the full chamber. “We want to raise the comfort level that people have. We want to do it right,” he said. “There’s no reason that we have to make people feel like they’re crowded or rushed.”...
Asked whether he’d had conversations with House Speaker Nancy Pelosi (D-CA) about moving cannabis bills forward this Congress, Blumenauer said there’s been consistent communication between their offices and that the speaker is “very sympathetic” to the issue and “understands the necessity of reform.”
There are 26 initial cosponsors — half Democrats and half Republicans—on the House version. Reps. Ro Khanna (D-CA), Lou Correa (D-CA), Ed Perlmutter (D-CO), Matt Gaetz (R-FL) and Don Young (R-AK) are among those supporters. The previous version ended the 115th Congress with 45 cosponsors.
On the Senate side, there are 10 lawmakers initially signed on: Warren and Gardner, along with Sens. Catherine Cortez Masto (D-NV), Michael Bennet (D-CO), Amy Klobuchar (D-MN), Ron Wyden (D-OR), Dan Sullivan (R-AK), Kevin Cramer (R-ND), Lisa Murkowski (R-AK) and Rand Paul (R-KY)....
For the most part, the latest versions of the legislation are identical to the previous Congress’s bills, though there are two exceptions. Previously, there was a provision exempting hemp from the definition of marijuana, but that was removed—presumably because it is no longer needed in light of the passage of the 2018 Farm Bill, which federally legalized the crop.
The bigger change is that the new version contains a section that requires the Government Accountability Office to conduct a study on the “effects of marihuana legalization on traffic safety.” Among other data points, the office would be directed to collect info on “traffic crashes, fatalities, and injuries in States that have legalized marihuana use, including whether States are able to accurately evaluate marihuana impairment in those incidents.” A report on those effects would be due one year after the law is enacted.
This article in Roll Call, headlined "Marijuana bill could help Cory Gardner’s re-election chances. Will Senate GOP leaders get behind it?," provides some more insights into the politics in play. Here are excerpts:
The bill’s sponsors are confident the bill can pass — if it comes up for a vote. “If we get it on the floor of the Senate, it passes,” said Gardner. “If we get it on the floor of the House, it passes.”...
Gardner acknowledged the bill will have a harder time in the GOP-controlled Senate than in the Democrat-led House, saying he was working to convince Judiciary Chairman Lindsey Graham to advance the bill and Majority Leader Mitch McConnell to eventually allow it to come to a floor vote. Graham, asked about the bill, said he hadn’t thought about marking it up. “I’m not very excited about it,” the South Carolina Republican said....
Gardner is up for re-election in 2020 in a state that legalized recreational marijuana, and allowing him a legislative win could help the GOP retain control of the Senate. On the other hand, Republican leadership may be loath to give some Democratic co-sponsors running in 2020 — whether for re-election or the presidency — political victories.
If Congress passes the proposal, Gardner said President Donald Trump will sign it. “The president has been very clear to me that he supports our legislation,” Gardner said. “He opposed the actions that were taken by the Attorney General [Jeff Sessions] to reverse the Cole memorandum and believes we have to fix this.” The Cole memorandum is Justice Department guidance against prosecuting federal marijuana laws in states that have legalized it.
Thursday, April 4, 2019
In my article, "Leveraging Marijuana Reform to Enhance Expungement Practices," I gave justified credit to work being done at the state and local level in California to ensure marijuana reform is operationalized as a form of criminal justice reform. I am pleased to see this work continuing, especially as described in this news release from the LA DA titled "Los Angeles, San Joaquin County District Attorneys Announce Code for America Partnership to Reduce, Clear Cannabis Convictions." Here is how the release starts:
District Attorneys Jackie Lacey of Los Angeles County and Tori Verber Salazar of San Joaquin County joined with Code for America today to announce a cutting-edge, criminal justice reform partnership to automatically clear more than 50,000 eligible cannabis convictions under Proposition 64.
The two counties are among the first in California to take part in Code for America’s pilot program that proactively identifies convictions that qualify for resentencing or dismissal under the voter-approved initiative in November 2016.
“We have partnered with Code for America to take on this monumental effort in the state’s most populous county,” District Attorney Lacey said. “As technology advances and the criminal justice system evolves, we as prosecutors must do our part to pursue innovative justice procedures on behalf of our constituents. This collaboration will improve people’s lives by erasing the mistakes of their past and hopefully lead them on a path to a better future. Helping to clear that path by reducing or dismissing cannabis convictions can result in someone securing a job or benefitting from other programs that may have been unavailable to them in the past. We are grateful to Code for America for bringing its technology to our office.”
“The war on drugs led to decades-long racial disparities in cannabis-related arrests and convictions,” said Los Angeles County Board Supervisor Mark Ridley-Thomas. “We have a responsibility to right these wrongs by utilizing the latest innovations in technology, such as Code for America’s Clear My Record initiative, to ensure that people who have been disproportionately harmed by the war on drugs get the second chance they deserve.”
“Since the passage of Propositions 47 and 64, the San Joaquin County District Attorney’s Office, in partnership with the Public Defender’s Office and the Superior Court, have worked collaboratively to successfully implement the law in a timely and efficient manner,” said San Joaquin County Public Defender Miriam Lyell in joint statement with District Attorney Tori Verber Salazar. “We have seen firsthand the capabilities of the Clear My Record tool to facilitate the record clearing process and provide a much-needed service to our community, restoring families along with tremendous cost savings to the People of the State of California. This powerful tool represents the best of public-private partnerships: harnessing the power of technology to create new pathways of opportunity for members of our community with convictions.”
“In the digital age, automatic record clearance is just common sense,” said Jennifer Pahlka, Founder and Executive Director, Code for America. “Thanks to the leadership of District Attorneys Lacey and Salazar, we’ve shown how records clearance can and should be done everywhere. When we do this right, we show that government can make good on its promises, especially for the hundreds of thousands who have been denied jobs, housing and other opportunities despite the passage of laws intended to provide relief. Clear My Record changes the scale and speed of justice and has the potential to ignite change across the state and the nation.”
Both offices have been working with Code for America since July 2018 to develop a system that examines cannabis convictions. There is estimated to be approximately 50,000 eligible convictions in Los Angeles County. There are an additional 4,000 eligible convictions in San Joaquin County.
Recognizing that California’s record clearance process was not designed for the digital age, this historic partnership demonstrates a growing momentum for technology-assisted record clearance in California. It builds on last month’s announcement that Code for America’s Clear My Record technology helped San Francisco dismiss and seal more than 8,000 cannabis convictions.
The references to Code for America’s work in San Francisco is both timely and a bit dated. I say that because of this recent tweet by the SF DA:
9,361 marijuana convictions-every single one since 1975 that is eligible pursuant to #Prop64-have officially been dismissed and sealed. Here’s the official court order. #SignedSealedDelivered pic.twitter.com/Kjg0SEfC5h— George Gascón (@GeorgeGascon) April 3, 2019
April 4, 2019 in Campaigns, elections and public officials concerning reforms, Criminal justice developments and reforms, History of Marijuana Laws in the United States, Recreational Marijuana Commentary and Debate, Who decides | Permalink | Comments (0)